>
Switch to:

Allergy Therapeutics Additional Paid-In Capital

: $157.9 Mil(As of Jun. 2021)
View and export this data going back to 2004. Start your Free Trial

Allergy Therapeutics's quarterly additional paid-in capital increased from Jun. 2020 ($140.9 Mil) to Dec. 2020 ($151.3 Mil) and increased from Dec. 2020 ($151.3 Mil) to Jun. 2021 ($157.9 Mil).

Allergy Therapeutics's annual additional paid-in capital declined from Jun. 2019 ($142.7 Mil) to Jun. 2020 ($140.9 Mil) but then increased from Jun. 2020 ($140.9 Mil) to Jun. 2021 ($157.9 Mil).


Allergy Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Allergy Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
Additional Paid-In Capital
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 131.14 136.20 142.68 140.90 157.89

Allergy Therapeutics Semi-Annual Data
Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
Additional Paid-In Capital Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 142.68 147.54 140.90 151.31 157.89

Allergy Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Allergy Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics Business Description

Allergy Therapeutics logo
Industry
Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergy with aluminium-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics Headlines

No Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)